- Home
- NSTS vs ALGS Comparison
NSTS vs ALGS Comparison
Compare NSTS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | ALGS |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 43.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSTS | ALGS |
|---|---|---|
| Price | $12.40 | $7.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 1.8K | ★ 33.8K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | $256,000.00 | ★ $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.73 | $3.76 |
| 52 Week High | $13.06 | $13.69 |
Technical Indicators
Market Signals| Indicator | NSTS | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 47.30 |
| Support Level | $12.26 | $6.92 |
| Resistance Level | $12.74 | $7.50 |
| Average True Range (ATR) | 0.16 | 0.55 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 52.62 | 65.13 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.